Matt Outten

Matt joined QED with over 20 years of pharmaceutical/biotech experience, focusing on oncology and various product launches. Before joining QED, Matt held various leadership positions at Pharmacyclics, including VP of Marketing and Market Access, VP of Commercial Operations, and Chief Commercial Officer. During his time at Pharmacyclics, Matt led the successful launch of Imbruvica for chronic lymphocytic leukemia and spearheaded launches in 5 additional disease states. Matt has also held important roles across marketing, sales, and market access at pharmaceutical and biotech companies including Millennium, Schering Plough, and GlaxoSmithKline. Matt received his BA from Hamilton College, MBA from The University of Delaware, and ALM from Harvard.